Q2 FY2026 · ended Jun 30, 2026 · Revenue $0 · Filed Aug 14, 2026
Annovis Bio, Inc. (ANVS) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $0 and a net loss of $14.8 million.
Revenue
$0
Net income
$-14.82M
-138.3% vs year-ago quarter
Operating cash flow
$-21.91M
-329.2% vs year-ago quarter
Free cash flow
—
EPS
$-0.40
-25.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
42.61M
+118.6% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ANVS (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Malvern, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1477845
- Former names
- QR Pharma, Inc. (until Mar 15, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$14.4M | -$18.0M | -$9.7M | -$7.4M | -$6.3M |
| Net income | -$14.8M | -$17.6M | -$9.8M | -$7.3M | -$6.2M |
| Diluted EPS | -$0.40 | -$0.63 | -$0.39 | -$0.37 | -$0.32 |
| Operating cash flow | -$21.9M | -$9.0M | -$8.9M | -$3.5M | -$5.1M |
| Total assets | $22.0M | $16.2M | $21.1M | $17.2M | $21.5M |
| Total liabilities | $26.3M | $13.1M | $4.2M | $4.0M | $3.1M |
| Stockholders' equity | -$4.3M | $3.1M | $16.9M | $13.2M | $18.3M |
| Cash and investments | $18.7M | $14.2M | $19.5M | $15.3M | $17.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
Nov 4, 2026 | Nov 3, 2026 |
| 8-K |
Current report
Listing notice, Regulation FD disclosure
|
Oct 30, 2026 | Oct 29, 2026 |
| 8-K |
Current report
Other events
|
Oct 20, 2026 | Oct 19, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
All 314 Annovis Bio, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.